Watch IKT. Know when insiders buy.
One email the day a filing lands. Free.
IKT
Inhibikase Therapeutics, Inc.
2.30
−0.01 −0.43%
USD · close Sep 17
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
52
WATCH · shorts 52
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $320.9MP/E —DIV YIELD —FCF YIELD -13.28%REV TTM —NET INCOME −$60.6MNET CASH $178.4M52W 1.41 – 2.52SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $0 | — | — | −$21.1M | −$19.6M | — | -0.11 | −$12.4M | $0 | −$12.4M | Aug 11 |
| Q1 2026 · Mar 31 | $0 | — | — | −$17.8M | −$16.4M | — | -0.10 | −$12.1M | $0 | −$12.1M | Aug 11 |
| Q4 2025 · Dec 31derived | — | — | — | −$13.8M | −$12.7M | — | -0.09 | −$7.5M | $0 | −$7.5M | Mar 26 |
| Q3 2025 · Sep 30 | $0 | — | — | −$12.8M | −$11.9M | — | -0.13 | −$10.6M | $0 | −$10.6M | Nov 14 |
| Q2 2025 · Jun 30 | $0 | — | — | −$10.8M | −$9.9M | — | -0.11 | −$5.6M | $0 | −$5.6M | Aug 11 |
| Q1 2025 · Mar 31 | $0 | — | — | −$14.6M | −$13.7M | — | -0.15 | −$4.1M | $13K | −$4.1M | Aug 11 |
| Q4 2024 · Dec 31derived | $0 | −100.0% | — | −$12.9M | −$12.1M | — | 0.87 | −$5.3M | $0 | −$5.3M | Mar 26 |
| Q3 2024 · Sep 30 | $0 | −100.0% | — | −$5.8M | −$5.8M | — | -0.65 | −$4.9M | $0 | −$4.9M | Nov 14 |
| Q2 2024 · Jun 30 | $0 | — | — | −$5.1M | −$5M | — | -0.66 | −$5.1M | $0 | −$5.1M | Nov 14 |
| Q1 2024 · Mar 31 | $0 | — | — | −$4.8M | −$4.6M | — | -0.73 | −$3.9M | $0 | −$3.9M | Nov 14 |
| Q4 2023 · Dec 31derived | $1 | — | — | −$4.4M | −$4.2M | — | -0.23 | −$3.4M | $0 | −$3.4M | Mar 27 |
| Q3 2023 · Sep 30 | $80K | — | — | −$4.8M | −$4.6M | — | -0.86 | −$4.1M | $0 | −$4.1M | Nov 14 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | −$52M | −$48.3M | — | -0.49 | −$27.8M | $13K | −$27.8M | — | — |
| FY2024 · to Dec 31 | $0 | — | −$28.6M | −$27.5M | — | -1.16 | −$19.1M | $0 | −$19.1M | — | — |
| FY2023 · to Dec 31 | $261K | — | −$20.1M | −$19M | -7304.7% | -3.16 | −$18.1M | $14K | −$18.1M | — | — |
| FY2022 · to Dec 31 | $123K | — | −$18.1M | −$18.1M | -14625.9% | -4.28 | −$17.4M | $243K | −$17.6M | — | — |
| FY2021 · to Dec 31 | $3.1M | — | −$14.8M | −$14.8M | -476.9% | -0.81 | −$14.3M | $0 | −$14.3M | — | — |
| FY2020 · to Dec 31 | $698K | — | −$2.8M | −$2.8M | -407.7% | -0.35 | −$1.1M | — | — | — | — |
Every number comes from Inhibikase Therapeutics, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.